Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Sun Yat-sen University

Status and phase

Unknown

Phase 2

Conditions

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Treatments

Drug: Chidamide

Study type

Interventional

Funder types

Other

Identifiers

NCT03245905

CSIIT-B09

Details and patient eligibility

About

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide as a single-agent treatment in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

Full description

Patients with relapsed /refractory aggressive B cell lymphoma usually have a poor prognosis. These patients cannot be treated successfully or tolered with the conventional chemotherapy. Epigenetic changes in B-cell lymphoma. Thus, epigenetic agents may offer potential improvment of clinical outcomes. Chidamide is a new type of oral histone deacetylase inhibitor. Our exploratory research found that Chidamide was effect in some relapsed /refractory B cell lymphoma patients

. Thus, we will evaluate the efficacy and safety of Chidamide in the patients with aggressive relapsed refractory B cell lymphoma failed from second line chemotherapy.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed as B-cell Non-Hodgkin's Lymphoma (NHL) according to "2008 WHO classification of tumors of haematopoietic and lymphoid tissues", including Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), transformed indolent lymphoma (TL), and other subtypes that investigators consider to be appropriate to be enrolled;
Patients achieved CR or PR in previous cytotoxic chemotherapy, and relapsed later than 6 months after remission;
Patients with DLBCL, FL grade3, MALT, LPL and SLL received at least two chemotherapy regimens, and Patients with FL grade1-2 received at least three chemotherapy regimens;
At least one measurable lesion with a longest diameter >1.5cm or a short axis >1.0cm;
Age18-75 years;
ECOG performance status 0-2;
Life expectancy no less than 3 months;
Functions within 7 days prior to enrollment: Blood routine test: Hb ≥ 80g/L, absolute neutrophil count ≥1.5 × 109/L, platelet ≥60 × 109/L; Total bilirubin ≤ 1.5 times of normal maximum, ALT/AST≤ 2.5 times of normal maximum, for patients with liver metastasis ALT/AST≤ 5 times of normal maximum; serum creatinin≤1.5 times of normal maximum or CCr≥ 60ml/min;
LVEF ≥ 50% by echocardiography;
Contraception during and 4 weeks after the study for patients at child bearing age;
Patients have signed the Informed Consent Form.

Exclusion criteria

Patients received Chidamide treatment within 6 months prior to enrollment;
Patients with Burkitt Lymphoma, B-lymphoblastic lymphoma, central nervous system lymphoma and HIV-Associated Lymphoma;
Patients with a "currently active" second malignancy;
Patients not recovered from non-hematologic toxicities within 4 weeks prior to enrollment due to chemotherapy, radiation and immunotherapy;
Patients receiving or received corticosteroids within 2 weeks prior to enrollment;
Patients with cumulative life time dose of Doxorubicin > 450mg/m2;
Patients who have been treated with any investigational drug within 4 weeks prior to enrollment;
Women during pregnancy or lactation;
Patients with active infection, medical conditions, or mental disorders;
Patients with active infection of HBV, HCV or HIV;
Congestive heart failure (NYHA grade III/IV), myocardial infarction within 6 months, QTc elongation with clinical significance (≥480ms), hypertension BP≥150/100 mmHg and symptomatic coronary heart disease that require treatment;
Patients with drug abuse, long term alcoholism that may impact the results of the trial;
Non-appropriate patients for the trial according to the judgment of the investigators.